Why the study?
Therapy of acute coronary syndrome is rapidly evolving due to development of new oral antiplatelet agents with different efficacy and safety profiles compared to clopidogrel.
Do newer oral P2Y12 inhibitors (prasugrel, ticagrelor) improve outcomes compared to clopidogrel in patients with acute coronary syndromes?
Do newer oral P2Y12 inhibitors (prasugrel, ticagrelor) improve outcomes compared to clopidogrel in patients with acute coronary syndromes?
Newer oral antiplatelet agents like prasugrel and ticagrelor are superior to clopidogrel for most ACS patients, though clopidogrel remains an alternative when newer agents are contraindicated or unavailable.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Widimský et al. (2012) conducted a review in Acute coronary syndromes (STEMI, NSTEMI, and unstable angina). Prasugrel and Ticagrelor vs. Clopidogrel was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: